CellWell record HH-522041
Vonoprazan-based dual therapy with amoxicillin or doxycycline versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a prospective, multicenter, open-label, randomized controlled trial
Haocheng Wang; Jun Wang; Lihong Shi; Guangxia Chen; Weixuan Yang; Chunming Fei; Xiaoli Huang; Zhimei Zhang; Xiujuan Wang; Jiahuan Gao; Zhenyu Zhang
2026
In plain language
In 579 patients with H. pylori, vonoprazan with low-dose amoxicillin was non-inferior to bismuth quadruple therapy, while vonoprazan with doxycycline had fewer adverse events but did not meet non-inferiority in the intention-to-treat analysis.
- Evidence
- Established
- Design
- Randomized controlled trial
Cite this record: https://thecellwell.org/studies/HH-522041
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.